What Can You Expect at the 11th Innate Killer Summit?
The long-standing legacy of the 11th Innate Killer Summit continues with this global gathering for innovators advancing NK, iNKT, and next-generation innate immune therapies. This year’s program is set to be the most electric and influential yet.
Across 3 high-energy days, the field’s visionary CEOs, scientists, investors, and leaders converge to define the breakthroughs shaping the future of NK-based medicine.
From first-in-human clinical data, durable long-term survival signals, cord-blood and iPSC-derived NK platforms, to cutting-edge engineering in cytokine-enhanced NK, multiplex edited cells, and logic-gated CAR-NK, attendees gain access to the most comprehensive and in-depth scientific insights driving the next era of innate therapies. Companies including Artiva, Glycostem, MiNK, NKore, NÖK, NKILT, Senti Bio, Alloplex, and leading academic centers such as the Rizvani Lab, unveil new clinical, mechanistic, and translational findings that are redefining what’s possible for cancer, autoimmunity, and viral disease.
The meeting also features an investment afternoon with top VCs, strategists, and biotech leaders, who will reveal what wins funding in today’s competitive landscape and how companies can de-risk platforms, validate clinical readiness, and accelerate toward commercial impact.
With unmatched networking, deep technical discussions, and exclusive data releases, the 11th Innate Killer Summit is the must-attend event for anyone shaping the future of innate cell therapy and immune engineering.
Unmissable Event Highlights
CEO Panel: Shaping the Next Era of Innate & NK-Cell Therapies
This opening session brings together 6 leading CEOs to explore the scientific, clinical, and commercial inflection points that will define the next 3–5 years of innate and NK-cell therapeutic innovation.
Clinical Momentum in Innate Cell Therapies: Emerging Data from Leading Developers
This highlight session will showcase recent clinical progress from NOK Therapeutics, MiNK, NKore, Artiva, and Glycostem, emphasizing advancing safety signals, early efficacy trends, and the translational insights shaping the next generation of NK- and innate-based therapies.
AI Advantage Session: Accelerating Next Generation Innate Immunotherapies
This forward-looking session explores how AI and machine learning are transforming donor selection, CAR-NK engineering, and preclinical-to-clinical workflows, unlocking faster, smarter, and more effective strategies to boost the impact and precision of innate immunotherapies.
Investor Power Session: Fueling the Next Wave of Innate Cell Therapy Breakthroughs
This high-impact investor forum brings top VCs, strategics, and industry leaders together to reveal what it takes to win capital in today’s competitive landscape, spotlighting how companies can de-risk their platforms, showcase clinical and manufacturing readiness, and build financing engines that propel innate cell therapies from early development to market-shaping success.
Explore the Agenda
- 22+ Expert Speakers
- 8+ Sessions of New Clinical Data
- 3 days of Expert Content
- 1 CEO Panel
- The World’s Only Industry Forum Dedicated to NK Cell Therapies
Attending Companies Include
Explore the Agenda
Discover the latest breakthroughs shaping NK and innate immune cell therapy in our expertly curated program. Gain actionable insights across engineering, manufacturing, persistence, and clinical development through data-rich presentations, collaborative roundtables, and brand-new strategic discussions built to tackle today’s biggest challenges in the NK space.
Partner With Us
Stand with the leaders driving the future of NK cell therapy. Position your brand at the heart of this legacy meeting and align with innovators seeking best-in-class tools, technologies, and partnerships. Showcase your solutions to the exact decision-makers shaping next-generation innate immune therapeutics.
Join Innate Immunity Experts
Connect with a highly engaged community of scientists, investors, academics and industry pioneers committed to advancing NK-based treatments. Be part of the most meaningful conversations in the field and build the relationships that will define the next wave of innovation in innate cell therapy.